Brief: Jubilant Pharmova Completes Safety Studies For Novel Oral Formulation Of Remdesivir
April 19 (Reuters) - Jubilant Pharmova Ltd JUBA.NS :
* COMPLETES SAFETY STUDIES IN ANIMALS, HEALTHY HUMANS IN
INDIA
USING NOVEL ORAL FORMULATION OF REMDESIVIR
* HAS SOUGHT AUTHORIZATION FOR ADDITIONAL STUDIES FOR NOVEL
ORAL
REMDESIVIR FORMULATION FROM INDIA REGULATORS
* PROPOSED ORAL REMDESIVIR TREATMENT FOR COVID-19 EXPECTED
TO BE
FOR 5 DAYS
Source text for Eikon: ID:nBSEbvSC3k
Further company coverage: JUBA.NS
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Jubilant Pharmova
See all newsBrief: Jubilant Pharmova Sept-Quarter Consol Net Profit 312 Million Rupees
Brief: Jubilant Pharmova Says Jubilant Therapeutics Announces Oral Presentation Of Preliminary Phase 1 Clinical Data For JBI-802
India New Issue-Jubilant Pharmova to issue 3-year bonds, bankers say
India's Jubilant Pharmova eyes $150 mln through rupee debt sale, bankers say
Brief: Jubilant Pharmova To Consider Raising Of Funds Through Issuance Of Non- Convertible Debentures